Author/Authors :
Gholami, Milad Department of Medical Genetics - School of Medicine - Shahid BeheshtiUniversity of Medical Sciences, Tehran, Iran , Bayat, Sahar Department of Medical Genetics - Faculty of Medicine - Tabriz University of Medical Sciences, Iran , Manoochehrabadi, Saba Department of Medical Genetics - School of Medicine - Shahid BeheshtiUniversity of Medical Sciences, Tehran, Iran , Pashaiefar, Hossein Department of Medical Genetics - School of Medicine - Tehran University of Medical Sciences, Iran , Omrani, Davood Department of Medical Genetics - School of Medicine - Shahid BeheshtiUniversity of Medical Sciences, Tehran, Iran , Jalaeikhoo, Hasan AJA Cancer Research Center (ACRC) - University of Medical Sciences, Tehran, Iran , Yassaee, Vahid Reza Genomic Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ebrahimpour, Mohammad Reza Genetics Research Center - University of Social Welfare and Rehabilitation Sciences, Tehran, Iran , Behjati, Farkhondeh Genetics Research Center - University of Social Welfare and Rehabilitation Sciences, Tehran, Iran , Mirfakhraie, Reza Department of Medical Genetics - School of Medicine - Shahid BeheshtiUniversity of Medical Sciences, Tehran, Iran
Abstract :
Background:The pathogenicity of acute myeloid leukemia (AML) is highly influenced by genetic alterations,
such as chromosomal abnormalities. Additionally, aberrations in the mechanisms involved in gene expression
have been identified to have a role in the development of AML. Contradictory evidence has been reported
concerning the expression of the CEBPA gene in AML patients. Additionally, investigation into the expression
of the CEBPA-AS gene has yet to be explored in AML patients. The aim of the present study was to investigate
the relationship between the expression of the CEBPA and CEBPA-AS genes and AML in Iranian patients.
Methods:Using quantitative real-time PCR, the expression of the CEBPA and CEBPA-AS genes was examined
in the peripheral blood samples of 58 patients with de novo adult AML, and in 20 healthy controls.
Results:Overall,CEBPAexpression analysis showed a significant up-regulation in AML patients compared with
healthy controls. Interestingly, a significant up-regulation of CEBPA was detected in the male AML patients.
Significant CEBPA over-expression was observed in M0 (p-value=0.0001), M3 (p-value= 0.012) and M4 (pvalue=0.000) FAB subtypes. Our data has also demonstrated thatCEBPAexpression is up-regulated in favorable
(p-value= 0.006) and adverse (p-value= 0.042) cytogenetic risk groups. In addition, the expression of CEBPA
was significantly increased in AML patients with an abnormal karyotype. Ectopic expression of CEBPA-AS was
detected in seven of the AML patients.
Conclusions: Our study provides evidence for the up-regulation of CEBPA and the ectopic expression of
CEBPA-AS in AML patients, suggesting that these two genes may play an important role in the pathogenesis of
AML. The role of CEBPA and CEBPA-AS in AML patients should be further explored. This will offer potential
opportunities for the development of novel treatment strategies.
Keywords :
Acute Myeloid Leukemia , CEBPA , CEBPA-AS , de novo , Expression
